We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Turn-Key PCR Solution Enables On-Site, Near Patient Testing for Monkeypox Virus

By LabMedica International staff writers
Posted on 30 Jun 2022
Print article
Image: DNA test for Monkeypox (Photo courtesy of Anitoa Systems)
Image: DNA test for Monkeypox (Photo courtesy of Anitoa Systems)

The World Health Organization has reported that over 2,100 people in 42 countries have been diagnosed with Monkeypox as of June 15, nearly all during the past two months. This makes it important for healthcare providers worldwide to have a preparedness plan. Now, a turn-key PCR solution for testing Monkeypox is designed to be carry out on-site, near patient, thus avoiding the need to transport patient samples to central labs for testing.

The CE-marked portable solution from Anitoa Systems (Sunnyvale, CA, USA) includes one of a family small foot-print real time PCR instruments called the Maverick qPCR, with an extraction-free multiplex PCR reagent that tests OPXV/MPXV gene-targets in the skin lesion sample from patients suspected of infection with Monkeypox. Anitoa's Maverick line of multiplex real time PCR devices are lab-accurate, fast, portable and calibration-free. They can operate on battery power (including car battery) and takes up very little bench space.

Maverick qPCR instruments are built on Anitoa's proprietary CMOS biosensor technology. They have been used widely for on-site testing of food, environment samples and agriculture products due to its rugged all solid-state design, small form factor, and lower operation cost. Already having a presence in Africa, Anitoa has begun deploying its near-patient Monkeypox test in selected clinics in Africa and is prepared to deliver its Monkeypox test solution world-wide when the need arises. Anitoa's Monkeypox detection solution is part of an on-going program at the company to develop tests to help combat a series of neglected tropical diseases in low resource settings. These tests currently include IVDR tests for Dengue, Yellow Fever, and Malaria

"We are closely monitoring the situation of Monkeypox infections around the world and tailoring our test solutions to the needs of the people affected," said Zhimin ding, CEO of Anitoa Systems, LLC.

Related Links:
Anitoa Systems

Gold Supplier
Real-Time PCR System
STC-96A Plus
Zika Virus IgM µ-Capture ELISA
Anti-HIV 1/2 ELISA Test
HIV 1/2 Antibody (3rd) Test Kit (ELISA)
Automatic Chemistry Analyzer

Print article
IIR Middle East



view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.